ADMA Biologics Statistics
Total Valuation
ADMA Biologics has a market cap or net worth of $3.80 billion. The enterprise value is $3.85 billion.
| Market Cap | 3.80B |
| Enterprise Value | 3.85B |
Important Dates
The next estimated earnings date is Wednesday, November 6, 2024, after market close.
| Earnings Date | Nov 6, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
ADMA Biologics has 233.08 million shares outstanding. The number of shares has increased by 10.28% in one year.
| Shares Outstanding | 233.08M |
| Shares Change (YoY) | +10.28% |
| Shares Change (QoQ) | +2.43% |
| Owned by Insiders (%) | 1.84% |
| Owned by Institutions (%) | 90.91% |
| Float | 228.80M |
Valuation Ratios
The trailing PE ratio is 109.84 and the forward PE ratio is 27.56. ADMA Biologics's PEG ratio is 1.38.
| PE Ratio | 109.84 |
| Forward PE | 27.56 |
| PS Ratio | 11.27 |
| Forward PS | 9.17 |
| PB Ratio | 20.19 |
| P/FCF Ratio | 57.04 |
| PEG Ratio | 1.38 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 40.54, with an EV/FCF ratio of 57.84.
| EV / Earnings | 110.80 |
| EV / Sales | 11.67 |
| EV / EBITDA | 40.54 |
| EV / EBIT | 44.44 |
| EV / FCF | 57.84 |
Financial Position
The company has a current ratio of 6.87, with a Debt / Equity ratio of 0.75.
| Current Ratio | 6.87 |
| Quick Ratio | 2.68 |
| Debt / Equity | 0.75 |
| Debt / EBITDA | 1.45 |
| Debt / FCF | 2.12 |
| Interest Coverage | 4.30 |
Financial Efficiency
Return on equity (ROE) is 20.77% and return on invested capital (ROIC) is 17.27%.
| Return on Equity (ROE) | 20.77% |
| Return on Assets (ROA) | 15.07% |
| Return on Capital (ROIC) | 17.27% |
| Revenue Per Employee | $529,237 |
| Profits Per Employee | $55,752 |
| Employee Count | 624 |
| Asset Turnover | 0.92 |
| Inventory Turnover | 1.03 |
Taxes
In the past 12 months, ADMA Biologics has paid $4.38 million in taxes.
| Income Tax | 4.38M |
| Effective Tax Rate | 11.19% |
Stock Price Statistics
The stock price has increased by +394.24% in the last 52 weeks. The beta is 0.62, so ADMA Biologics's price volatility has been lower than the market average.
| Beta (5Y) | 0.62 |
| 52-Week Price Change | +394.24% |
| 50-Day Moving Average | 17.84 |
| 200-Day Moving Average | 11.03 |
| Relative Strength Index (RSI) | 42.54 |
| Average Volume (20 Days) | 4,512,908 |
Short Selling Information
The latest short interest is 16.07 million, so 6.90% of the outstanding shares have been sold short.
| Short Interest | 16.07M |
| Short Previous Month | 17.08M |
| Short % of Shares Out | 6.90% |
| Short % of Float | 7.03% |
| Short Ratio (days to cover) | 2.09 |
Income Statement
In the last 12 months, ADMA Biologics had revenue of $330.24 million and earned $34.79 million in profits. Earnings per share was $0.15.
| Revenue | 330.24M |
| Gross Profit | 154.40M |
| Operating Income | 86.74M |
| Pretax Income | 39.17M |
| Net Income | 34.79M |
| EBITDA | 95.09M |
| EBIT | 86.74M |
| Earnings Per Share (EPS) | $0.15 |
Balance Sheet
The company has $88.24 million in cash and $141.40 million in debt, giving a net cash position of -$53.15 million or -$0.23 per share.
| Cash & Cash Equivalents | 88.24M |
| Total Debt | 141.40M |
| Net Cash | -53.15M |
| Net Cash Per Share | -$0.23 |
| Equity (Book Value) | 188.27M |
| Book Value Per Share | 0.81 |
| Working Capital | 259.51M |
Cash Flow
In the last 12 months, operating cash flow was $73.01 million and capital expenditures -$6.37 million, giving a free cash flow of $66.64 million.
| Operating Cash Flow | 73.01M |
| Capital Expenditures | -6.37M |
| Free Cash Flow | 66.64M |
| FCF Per Share | $0.29 |
Margins
Gross margin is 46.75%, with operating and profit margins of 26.27% and 10.53%.
| Gross Margin | 46.75% |
| Operating Margin | 26.27% |
| Pretax Margin | 11.86% |
| Profit Margin | 10.53% |
| EBITDA Margin | 28.79% |
| EBIT Margin | 26.27% |
| FCF Margin | 20.18% |
Dividends & Yields
ADMA Biologics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -10.28% |
| Shareholder Yield | -10.28% |
| Earnings Yield | 0.92% |
| FCF Yield | 1.75% |
Analyst Forecast
The average price target for ADMA Biologics is $15.50, which is -4.97% lower than the current price. The consensus rating is "Strong Buy".
| Price Target | $15.50 |
| Price Target Difference | -4.97% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 16.53% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ADMA Biologics has an Altman Z-Score of 4.66 and a Piotroski F-Score of 8.
| Altman Z-Score | 4.66 |
| Piotroski F-Score | 8 |